Readnour Robin Shane — SEC Form 4 filings
SEC reporting owner CIK 1914883. 13 Form 4 filings on record with FilingPulse; latest filed 2026-09-11.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-01-12 to 2026-09-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 14 legs across 3 filings — 335,000 shares, $405,521 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 12 legs across 5 filings — 57,723 shares, $428,372 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: sale of 18,706 shares @ $6.01 ($112,389) in AN2 Therapeutics, Inc., filed 2026-08-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | Director | 13 | 14 legs · 335,000 sh · $405,521 | 12 legs · 57,723 sh · $428,372 | 8 |
Form 4 filings — Readnour Robin Shane
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 523 @ $6.02 · Sale (S): 585 @ $6.02 | EDGAR |
| 2026-09-08 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 2,877 @ $6.07 · Sale (S): 3,223 @ $6.07 · Sale (S): 4,725 @ $6.02 · Sale (S): 5,294 @ $6.02 | EDGAR |
| 2026-08-19 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 16,696 @ $6.01 · Sale (S): 18,706 @ $6.01 | EDGAR |
| 2026-03-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 20,724 (derivative) · Disposition to issuer (D): 20,724 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-02-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 19,111 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 9,077 @ $0 | EDGAR |
| 2024-12-10 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 12,711 @ $1.45 · Purchase (P): 6,517 @ $1.45 · Purchase (P): 12,289 @ $1.43 · Purchase (P): 18,483 @ $1.43 · Purchase (P): 5,000 @ $1.49 · Purchase (P): 5,000 @ $1.49 | EDGAR |
| 2024-11-27 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 12,500 @ $1.39 · Purchase (P): 12,500 @ $1.39 · Purchase (P): 25,000 @ $1.42 · Purchase (P): 25,000 @ $1.42 | EDGAR |
| 2024-11-21 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 75,000 @ $1.03 · Purchase (P): 75,000 @ $1.04 · Purchase (P): 25,000 @ $1.16 · Purchase (P): 25,000 @ $1.15 | EDGAR |
| 2024-06-21 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 64,503 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 706 @ $21.92 · Sale (S): 719 @ $21.91 | EDGAR |
| 2024-01-12 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 1,869 @ $21.93 · Sale (S): 1,800 @ $21.92 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1914883 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →